Given our observations that the combination of AVB-500 plus bevacizumab was more effective than either drug alone in reducing both tumor cell VEGF secretion and blood vessel formation in vitro, we next sought to determine their effects on tumor growth in vivo. Here, VEGFA is linked to neoplasm.